肺がん・悪性胸膜中皮腫
-
011101_IP(CDDP+CPT-11)(SCLC) (PDF:108 KB)
-
011102_CBDCA+CPT-11 (PDF:98 KB)
-
011103_CPT-11 (PDF:61 KB)
-
011104_EP(CDDP+ETP) (PDF:107 KB)
-
011105_CBDCA+ETP (PDF:96 KB)
-
011106_AMR (PDF:81 KB)
-
011107_NGT (PDF:73 KB)
-
011208_CDDP+ETP+RT (PDF:111 KB)
-
011209_split-CDDP+ETP+RT (PDF:121 KB)
-
012101_CDDP+VNR (PDF:117 KB)
-
012102_CDDP+GEM (PDF:112 KB)
-
012103_CBDCA+GEM (PDF:101 KB)
-
012104_PEM (PDF:98 KB)
-
012105_PEM+BV (PDF:126 KB)
-
012106_CDDP+DTX (PDF:101 KB)
-
012107_CBDCA+DTX (PDF:90 KB)
-
012108_DTX (PDF:80 KB)
-
012109_DTX+BV (PDF:111 KB)
-
012110_CBDCA+PTX+BV (PDF:128 KB)
-
012111_CBDCA+PTX (PDF:97 KB)
-
012112_weeklyPTX+CDBCA (PDF:113 KB)
-
012113_VNR (PDF:77 KB)
-
012114_CARNAVAL(nab-PTX+CBDCA+BV) (PDF:119 KB)
-
012116_TKI+BV (PDF:109 KB)
-
012117_CBDCA+PEM+BV (PDF:117 KB)
-
012214_CDDP+DTX+RT (PDF:111 KB)
-
012215_CBDCA+PTX+RT (PDF:74 KB)
-
012220_nab-PTX+CBDCA (PDF:109 KB)
-
012221_low dose CBDCA+RT (PDF:72 KB)
-
012222_CBDCA+S-1 (PDF:89 KB)
-
012224_weekly nab-PTX (PDF:88 KB)
-
012225_CBDCA+VNR (PDF:106 KB)
-
012227_CDGP+DTX (PDF:109 KB)
-
012230_Nivolumab (PDF:80 KB)
-
012238_IP(CDDP+CPT-11)(NSCLC) (PDF:106 KB)
-
012239_RAM+DTX (PDF:109 KB)
-
012240_CBDCA(AUC6)+PEM (PDF:112 KB)
-
012241_Pembrolizumab (PDF:70 KB)
-
012253_Atezolizumab (PDF:82 KB)
-
012260_Pembrolizumab+CDDP+PEM (PDF:166 KB)
-
012261_Pembrolizumab+CBDCA+PEM (PDF:144 KB)
-
012262_Pembrolizumab+PEM(maintenance) (PDF:133 KB)
-
012263_Pembrolizumab+CBDCA+nab-PTX (PDF:144 KB)
-
012264_Pembrolizumab(maintenance) (PDF:111 KB)
-
012265_CDDP(split)+VNR (PDF:110 KB)
-
012266_Atezolizumab+CBDCA+ETP (PDF:116 KB)
-
012267_Atezolizumab(maintenance) (PDF:114 KB)
-
012268_Atezolizumab+CBDCA+nab-PTX (PDF:145 KB)
-
012271_Durvalumab+CDDP+ETP (PDF:138 KB)
-
012272_Durvalumab(maintenance) (PDF:86 KB)
-
012275_Nivolumab(Q4W) (PDF:80 KB)
-
012281_RAM+erlotinib gefitinib (PDF:101 KB)
-
012282_Necitumumab+CDDP+GEM (PDF:143 KB)
-
012283_Necitumumab(maintenance) (PDF:100 KB)
-
012284_Atezolizumab+BV+CBDCA+PTX (PDF:156 KB)
-
012285_Atezolizumab+BV(maintenance) (PDF:111 KB)
-
012288_Durvalumab+CBDCA+ETP (PDF:116 KB)
-
012290_Pembrolizumab+CBDCA+PTX (PDF:139 KB)
-
012291_Atezolizumab+CDDP+PEM (PDF:169 KB)
-
012292_Atezolizumab+CBDCA+PEM (PDF:145 KB)
-
012293_Atezolizumab+PEM(maintenance) (PDF:133 KB)
-
012294_Atezolizumab(adjuvant) (PDF:91 KB)
-
012295_CDDP+S-1+RT (PDF:123 KB)
-
012296_Durvalumab+Tremelimumab+CBDCA+nab-PTX (PDF:148 KB)
-
012297_Durvalumab+Tremelimumab(maintenance1) (PDF:117 KB)
-
012298_Durvalumab(maintenance2) (PDF:115 KB)
-
012299_Nivolumab+Ipilimumab (PDF:94 KB)
-
012300_Durvalumab(maintenance after CRT) (PDF:89 KB)
-
012303_Trastuzumab Deruxtecan (PDF:105 KB)
-
012307_Nivolumab+CBDCA+PEM(neo adjuvant) (PDF:141 KB)
-
012308_Nivolumab+CDDP+PEM(neo adjuvant) (PDF:163 KB)
-
012309_Nivolumab+CBDCA+PTX(neo adjuvant) (PDF:134 KB)
-
012310_CBDCA+PEM+Osimertinib (PDF:119 KB)
-
012311_CDDP+PEM+Osimertinib (PDF:123 KB)
-
012312_PEM(maintenance)+Osimertinib (PDF:109 KB)
-
012314_Pembrolizumab+CDDP+GEM(neo adjuvant) (PDF:162 KB)
-
012315_Pembrolizumab+CDDP+PEM(neo adjuvant) (PDF:162 KB)
-
012316_Pembrolizumab(adjuvant) (PDF:87 KB)
-
013101_CDDP+PEM (PDF:118 KB)
-
013102_CBDCA(AUC5)+PEM (PDF:111 KB)
-
013103_CDDP+PEM+BV (PDF:135 KB)
-
013106_Nivolumab (PDF:82 KB)
-
013107_Nivolumab(Q4W) (PDF:84 KB)
-
013108_Nivolumab+Ipilimumab (PDF:94 KB)
乳がん
-
020101_CMF(CPA+MTX+5-FU) (PDF:93 KB)
-
020102_AC(DXR+CPA) (PDF:107 KB)
-
020103_FEC(5-FU+EPI+CPA) (PDF:99 KB)
-
020104_EC(EPI+CPA) (PDF:93 KB)
-
020105_DTX (PDF:80 KB)
-
020106_DTX+Trastuzumab(1cycle) (PDF:93 KB)
-
020107_DTX+Trastuzumab(2cycle-) (PDF:93 KB)
-
020108_PTX (PDF:82 KB)
-
020109_PTX+Trastuzumab(1cycle) (PDF:95 KB)
-
020110_PTX+Trastuzumab(2cycle-) (PDF:94 KB)
-
020114_triweekly Trastuzumab(1cycle) (PDF:64 KB)
-
020115_triweekly Trastuzumab(2cycle-) (PDF:65 KB)
-
020116_weekly Trastuzumab(1cycle) (PDF:63 KB)
-
020117_weekly Trastuzumab(2cycle-) (PDF:62 KB)
-
020118_TC(DTX+CPA) (PDF:95 KB)
-
020119_TC(DTX+CPA)+Trastuzumab(1cycle) (PDF:107 KB)
-
020120_TC(DTX+CPA)+Trastuzumab(2cycle-) (PDF:107 KB)
-
020121_VNR (PDF:70 KB)
-
020122_VNR+Trastuzumab(1cycle) (PDF:89 KB)
-
020123_VNR+Trastuzumab(2cycle-) (PDF:89 KB)
-
020124_GEM (PDF:82 KB)
-
020125_GEM+Trastuzumab(1cycle) (PDF:105 KB)
-
020126_GEM+Trastuzumab(2cycle-) (PDF:101 KB)
-
020127_GEM+PTX (PDF:102 KB)
-
020128_GEM+PTX+Trastuzumab(1cycle) (PDF:113 KB)
-
020129_GEM+PTX+Trastuzumab(2cycle-) (PDF:111 KB)
-
020130_GEM+weeklyPTX (PDF:94 KB)
-
020131_GEM+weeklyPTX+Trastuzumab(1cycle) (PDF:117 KB)
-
020132_GEM+weeklyPTX+Trastuzumab(2cycle-) (PDF:120 KB)
-
020133_nab-PTX (PDF:85 KB)
-
020134_weeklyPTX+BV (PDF:112 KB)
-
020142_Eribulin (PDF:64 KB)
-
020153_Perjeta+Trastuzumab+DTX(1cycle) (PDF:103 KB)
-
020154_Perjeta+Trastuzumab+DTX(2cycle-) (PDF:98 KB)
-
020155_Perjeta+Trastuzumab(1cycle) (PDF:91 KB)
-
020156_Perjeta+Trastuzumab(2cycle-) (PDF:87 KB)
-
020157_Perjeta+Trastuzumab+PTX(1cycle) (PDF:84 KB)
-
020158_Perjeta+Trastuzumab+PTX(2cycle-) (PDF:81 KB)
-
020160_Perjeta+Trastuzumab+GEM(1cycle) (PDF:89 KB)
-
020161_Perjeta+Trastuzumab+GEM(2cycle-) (PDF:83 KB)
-
020162_Eribulin+Trastuzumab(1cycle) (PDF:83 KB)
-
020163_Eribulin+Trastuzumab(2cycle-) (PDF:82 KB)
-
020164_T-DM1 (PDF:70 KB)
-
020165_Perjeta+Trastuzumab+weeklyPTX(1cycle) (PDF:117 KB)
-
020166_Perjeta+Trastuzumab+weeklyPTX(2cycle-) (PDF:111 KB)
-
020167_Perjeta+Trastuzumab+Eribulin(1cycle) (PDF:84 KB)
-
020168_Perjeta+Trastuzumab+Eribulin(2cycle-) (PDF:79 KB)
-
020169_Perjeta+Trastuzumab+VNR(1cycle) (PDF:96 KB)
-
020170_Perjeta+Trastuzumab+VNR(2cycle-) (PDF:92 KB)
-
020171_CPT-11 (PDF:80 KB)
-
020233_Dose-Dense AC (PDF:108 KB)
-
020234_Dose-Dense PTX (PDF:100 KB)
-
020235_weeklyPTX+Trastuzumab(1cycle) (PDF:107 KB)
-
020236_weeklyPTX+Trastuzumab(2cycle-) (PDF:106 KB)
-
020237_GEM+BV (PDF:102 KB)
-
020238_Atezolizumab+nab-PTX (PDF:117 KB)
-
020239_Perjeta+Trastuzumab+CBDCA+DTX(1cycle) (PDF:129 KB)
-
020240_Perjeta+Trastuzumab+CBDCA+DTX(2cycle-) (PDF:127 KB)
-
020241_Trastuzumab Deruxtecan (PDF:102 KB)
-
020242_T-DM1(adjuvant) (PDF:87 KB)
-
020243_Pembrolizumab(Q3W)+CBDCA+GEM (PDF:126 KB)
-
020244_Pembrolizumab(Q6W)+CBDCA+GEM (PDF:129 KB)
-
020245_Pembrolizumab(Q3W)+nab-PTX (PDF:135 KB)
-
020246_Pembrolizumab(Q6W)+nab-PTX (PDF:128 KB)
-
020247_Pembrolizumab(Q3W)+PTX (PDF:129 KB)
-
020248_Pembrolizumab(Q6W)+PTX (PDF:123 KB)
-
020249_weeklyPTX (PDF:86 KB)
-
020250_Pembrolizumab+CBDCA(AUC1.5)+PTX (PDF:122 KB)
-
020251_Pembrolizumab+CBDCA(AUC5)+PTX (PDF:124 KB)
-
020252_Pembrolizumab+AC(DXR+CPA) (PDF:118 KB)
-
020253_Pembrolizumab (PDF:81 KB)
-
020254_Trastuzumab Deruxtecan(HER2-low) (PDF:101 KB)
-
020255_PHESGO(1cycle) (PDF:105 KB)
-
020256_PHESGO(2cycle-) (PDF:103 KB)
-
020257_weeklyPTX+PHESGO(1cycle) (PDF:142 KB)
-
020258_weeklyPTX+PHESGO(2cycle-) (PDF:137 KB)
-
020259_DTX+PHESGO(1cycle) (PDF:125 KB)
-
020260_DTX+PHESGO(2cycle-) (PDF:118 KB)
-
020261_Eribulin+PHESGO(1cycle) (PDF:122 KB)
-
020262_Eribulin+PHESGO(2cycle-) (PDF:116 KB)
-
020263_GEM+PHESGO(1cycle) (PDF:124 KB)
-
020264_GEM+PHESGO(2cycle-) (PDF:117 KB)
-
020265_VNR+PHESGO(1cycle) (PDF:127 KB)
-
020266_VNR+PHESGO(2cycle-) (PDF:119 KB)
-
020267_AC(DXR+CPA)(G-LASTA BodyPod) (PDF:108 KB)
胃がん
-
030101_CDDP+CPT-11 (PDF:77 KB)
-
030102_S-1+CDDP(short hydration) (PDF:104 KB)
-
030103_S-1+CPT-11 (PDF:69 KB)
-
030105_CPT-11 (PDF:61 KB)
-
030106_S-1+DTX (PDF:90 KB)
-
030107_DTX (PDF:73 KB)
-
030108_weeklyPTX (PDF:80 KB)
-
030110_Capecitabine+CDDP+Trastuzumab(1cycle) (PDF:139 KB)
-
030111_Capecitabine+CDDP+Trastuzumab(2cycle-) (PDF:139 KB)
-
030112_Capecitabine+CDDP (PDF:128 KB)
-
030114_nab-PTX (PDF:83 KB)
-
030115_CAPOX(Capecitabine+L-OHP) (PDF:112 KB)
-
030209_S-1+CDDP (PDF:103 KB)
-
030210_Ramucirumab (PDF:72 KB)
-
030211_weeklyPTX+Ramucirumab (PDF:111 KB)
-
030212_Nivolumab (PDF:83 KB)
-
030213_weekly nab-PTX (PDF:69 KB)
-
030214_weekly nab-PTX+Ramucirumab (PDF:111 KB)
-
030215_Capecitabine+Trastuzumab(1cycle) (PDF:113 KB)
-
030216_Capecitabine+Trastuzumab(2cycle-) (PDF:114 KB)
-
030217_Trastuzumab Deruxtecan (PDF:104 KB)
-
030218_Nivolumab(Q4W) (PDF:82 KB)
-
030219_SOX(S-1+L-OHP)+Nivolmab (PDF:107 KB)
-
030220_TAS-102+Ramucirumab (PDF:123 KB)
-
030221_CAPOX+Trastuzumab(1cycle) (PDF:119 KB)
-
030222_CAPOX+Trastuzumab(2cycle-) (PDF:117 KB)
-
030223_SOX(S-1+L-OHP)130mg m2 (PDF:99 KB)
-
030224_CAPOX+Zolbetuximab(1cycle) (PDF:157 KB)
-
030225_CAPOX+Zolbetuximab(2cycle-) (PDF:155 KB)
-
030226_mFOLFOX6+Zolbetuximab(1cycle) (PDF:442 KB)
-
030227_mFOLFOX6+Zolbetuximab(2cycle-) (PDF:439 KB)
食道がん
-
040101_DTX (PDF:80 KB)
-
040208_weeklyPTX (PDF:82 KB)
-
040209_Nivolumab (PDF:82 KB)
-
040210_Nivolumab(Q4W) (PDF:82 KB)
-
040213_Nivolumab+Ipilimumab (PDF:113 KB)
-
040214_Nivolumab(adjuvant)(Q4W) (PDF:107 KB)
大腸がん
-
050101_mFOLFOX6(l-LV+L-OHP+5-FU) (PDF:447 KB)
-
050102_mFOLFOX6(l-LV+L-OHP+5-FU)+BV (PDF:451 KB)
-
050105_FOLFIRI(l-LV+CPT-11+5-FU) (PDF:444 KB)
-
050106_FOLFIRI(l-LV+CPT-11+5-FU)+BV (PDF:452 KB)
-
050109_CPT-11+C-mab(1cycle) (PDF:106 KB)
-
050110_CPT-11+C-mab(2cycle-) (PDF:101 KB)
-
050113_CAPOX(Capecitabine+L-OHP) (PDF:110 KB)
-
050114_CAPOX(Capecitabine+L-OHP)+BV (PDF:117 KB)
-
050115_IRIS(CPT-11+S-1) (PDF:81 KB)
-
050116_FOLFIRI(l-LV+CPT-11+5-FU)+P-mab (PDF:453 KB)
-
050117_IRIS(CPT-11+S-1)+BV (PDF:86 KB)
-
050118_SOX(S-1+L-OHP)+BV (PDF:98 KB)
-
050120_P-mab (PDF:66 KB)
-
050121_Capecitabine+BV (PDF:98 KB)
-
050122_mFOLFOX6(l-LV+L-OHP+5-FU)+P-mab (PDF:455 KB)
-
050123_FOLFIRI(l-LV+CPT-11+5-FU)+RAM (PDF:462 KB)
-
050124_CPT-11+P-mab (PDF:77 KB)
-
050125_mFOLFOXIRI+BV(induction) (PDF:500 KB)
-
050126_5-FU+l-LV+BV(maintenance) (PDF:482 KB)
-
050127_TAS-102+BV (PDF:116 KB)
-
050133_C-mab(Q2W) (PDF:86 KB)
-
050134_Encorafenib+Binimetinib+C-mab(Q2W) (PDF:111 KB)
-
050135_Encorafenib+C-mab(Q2W) (PDF:106 KB)
-
050136_FOLFIRI+C-mab(Q2W) (PDF:469 KB)
-
050137_mFOLFOX6+C-mab(Q2W) (PDF:457 KB)
-
050138_Pertuzumab+Trastuzumab(1cycle) (PDF:95 KB)
-
050139_Pertuzumab+Trastuzumab(2cycle-) (PDF:97 KB)
肝臓がん
-
060207_low dose FP(5-FU+CDDP) (PDF:120 KB)
-
060208_Ramucirumab (PDF:91 KB)
-
060209_Atezolizumab+BV (PDF:180 KB)
-
060210_Durvalumab+Tremelimumab (PDF:87 KB)
-
060212_Durvalumab(maintenance) (PDF:81 KB)
胆道がん
-
070101_CDDP+GEM (PDF:75 KB)
-
070102_GEM (PDF:77 KB)
-
070103_GCS(GEM+CDDP+S-1) (PDF:102 KB)
-
070104_Durvalumab+CDDP+GEM (PDF:109 KB)
-
070105_Durvalumab+CDDP+GEM(-30kg) (PDF:108 KB)
-
070106_Durvalumab(maintenance) (PDF:83 KB)
-
070107_Durvalumab(maintenance)(-30kg) (PDF:85 KB)
-
070108_Pembrolizumab+CDDP+GEM (PDF:109 KB)
-
070109_Pembrolizumab+GEM(maintenance) (PDF:99 KB)
膵臓がん
-
080101_GEM (PDF:78 KB)
-
080103_S-1+GEM (PDF:90 KB)
-
080104_GEM+Erlotinib (PDF:92 KB)
-
080105_mFOLFIRINOX (PDF:476 KB)
-
080107_nab-PTX+GEM (PDF:91 KB)
-
080108_nal-IRI+5-FU l-LV (PDF:503 KB)
-
080109_mFOLFIRINOX(-CPT-11) (PDF:461 KB)
NET・NEC
-
081101_STZ+5-FU (PDF:104 KB)
-
081102_EP(CDDP+ETP) (PDF:109 KB)
-
081103_CPT-11 (PDF:75 KB)
-
081104_AMR (PDF:85 KB)
婦人科
-
100101_weeklyTC (PDF:97 KB)
-
100102_weeklyDC (PDF:90 KB)
-
101102_dose denseTC (PDF:109 KB)
-
101103_weeklyTN (PDF:94 KB)
-
101105_weeklyDN (PDF:85 KB)
-
101107_CPT-11+CBDCA (PDF:97 KB)
-
101108_CPT-11 (PDF:59 KB)
-
101109_GC(GEM+CBDCA) (PDF:108 KB)
-
101110_GEM (PDF:82 KB)
-
101111_DXL (PDF:81 KB)
-
101113_CD(CBDCA+DXL) (PDF:111 KB)
-
101114_DXL+GEM (PDF:102 KB)
-
101201_monthlyTC (PDF:98 KB)
-
101204_monthlyDC (PDF:94 KB)
-
101206_IP(CPT-11+CDDP) (PDF:100 KB)
-
101213,101214_CPB (PDF:141 KB)
-
101215,101216_CDB(PTX unfit) (PDF:140 KB)
-
101217_DXL+BV (PDF:95 KB)
-
101218_NGT+BV (PDF:91 KB)
-
102101_TP(PTX+CDDP) (PDF:108 KB)
-
103101_GD(GEM+DTX) (PDF:95 KB)
-
103202_IAP(IFM+THP+CDDP) (PDF:138 KB)
-
103203_AP(DXR+CDDP) (PDF:101 KB)
-
104103_ACT-D(pulse) (PDF:85 KB)
-
104104_ACT-D(5days) (PDF:87 KB)
泌尿器
-
111101_GC(GEM+CDDP) (PDF:119 KB)
-
111102_GEM+CBDCA (PDF:106 KB)
-
111103_GCP(GEM+CDDP+PTX) (PDF:126 KB)
-
111104_GEM+CBDCA+PTX (PDF:120 KB)
-
111105_GEM (PDF:78 KB)
-
111206_MVAC (PDF:137 KB)
-
111210_Pembrolizumab (PDF:65 KB)
-
111211_Avelumab (PDF:91 KB)
-
111212_Enfortumab Vedotin (PDF:91 KB)
-
111214_Nivolumab(adjuvant)(Q4W) (PDF:82 KB)
-
111215_Enfortumab Vedotin+Pembrolizumab (PDF:98 KB)
-
111216_Enfortumab Vedotin(maintenance) (PDF:85 KB)
-
112101_DTX (PDF:92 KB)
-
112104_Cabazitaxel (PDF:105 KB)
-
112105_DTX+Darolutamide (PDF:89 KB)
-
114102_Temsirolimus (PDF:56 KB)
-
114103_Nivolumab (PDF:73 KB)
-
114104_Nivolumab+Ipilimumab (PDF:87 KB)
-
114105_Pembrolizumab+Axitinib (PDF:94 KB)
-
114106_Avelumab+Axitinib (PDF:99 KB)
-
114107_Nivolumab+Cabozantinib (PDF:94 KB)
-
114108_Pembrolizumab+Lenvatinib (PDF:87 KB)
-
114109_Pembrolizumab(adjuvant)(Q6W) (PDF:86 KB)
悪性リンパ腫
-
120201_Rituximab (PDF:82 KB)
-
120202_CHOP (PDF:106 KB)
-
120203_R-CHOP (PDF:125 KB)
-
120204_CVP (PDF:105 KB)
-
120205_R-CVP (PDF:124 KB)
-
120206_THP-COP (PDF:113 KB)
-
120207_R-THP-COP (PDF:125 KB)
-
120222_ABVD (PDF:100 KB)
-
120223_Bendamustine (PDF:90 KB)
-
120224_R-Bendamustine(3days) (PDF:103 KB)
-
120245_Brentuximab Vedotin (PDF:76 KB)
-
120247_Nivolumab (PDF:76 KB)
-
120250_A-AVD (PDF:132 KB)
-
120251_G-CHOP(1cycle) (PDF:140 KB)
-
120252_G-CHOP(2-6cycle) (PDF:132 KB)
-
120253_G-CHOP(Obinutuzumab)(7-8cycle) (PDF:94 KB)
-
120254_G-CVP(1cycle) (PDF:132 KB)
-
120255_G-CVP(2-8cycle) (PDF:124 KB)
-
120256_G-Bendamustine(1cycle) (PDF:117 KB)
-
120257_G-Bendamustine(2-6cycle)(3days) (PDF:109 KB)
-
120258_Obinutuzumab(maintenance) (PDF:92 KB)
-
120268_R2(RIT+Lenalidomide)(1cycle) (PDF:97 KB)
-
120269_R2(RIT+Lenalidomide)(2-5cycle) (PDF:96 KB)
-
120270_Pembrolizumab (PDF:76 KB)
-
120271_A-CHP (PDF:129 KB)
-
120272_Pola-BR(1cycle) (PDF:128 KB)
-
120273_Pola-BR(2cycle-) (PDF:121 KB)
-
120275_Pola-R-CHP (PDF:138 KB)
-
120294_R-Bendamustine(2days) (PDF:101 KB)
-
120295_G-Bendamustine(2-6cycle)(2days) (PDF:108 KB)
-
120300_Rituximab(90min) (PDF:93 KB)
-
120301_R-CHOP(1day) (PDF:131 KB)
-
120302_R-CHOP(RIT90min) (PDF:134 KB)
-
120303_Epcoritamab(1cycle) (PDF:118 KB)
-
120304_Epcoritamab(2-3cycle) (PDF:102 KB)
-
120305_Epcoritamab(4-9cycle) (PDF:101 KB)
-
120306_Epcoritamab(10cycle-) (PDF:101 KB)
-
120307_R2(90min)(1cycle) (PDF:102 KB)
-
120308_R2(90min)(2-5cycle) (PDF:101 KB)
-
120309_Pola-R-CHP(RIT90min) (PDF:136 KB)
-
120310_Pola-BR(RIT90min) (PDF:125 KB)
-
120311_R-CVP(RIT90min) (PDF:120 KB)
-
120312_R-CVP(1day) (PDF:117 KB)
-
120321_DRC (PDF:97 KB)
-
120322_BDR(1cycle) (PDF:76 KB)
-
120323_BDR(2,5cycle) (PDF:98 KB)
-
120324_BDR(3,4cycle) (PDF:78 KB)
-
120325_G-CHOP(2-6cycle)(G short duration) (PDF:139 KB)
-
120326_G-CHOP(Obinutuzumab)(7-8cycle)(G short duration) (PDF:95 KB)
-
120327_G-CVP(2-8cycle)(G short duration) (PDF:131 KB)
-
120328_G-Bendamustine(2-6cycle)(G short duration) (PDF:109 KB)
-
120329_Obinutuzumab(maintenance)(G short duration) (PDF:95 KB)
多発性骨髄腫
-
130202_Bd (PDF:72 KB)
-
130204_weekly Bd (PDF:73 KB)
-
130205_Kd(1cycle) (PDF:96 KB)
-
130206_Kd(2cycle-) (PDF:84 KB)
-
130207_Bd(sc) (PDF:68 KB)
-
130208_weekly Bd(sc) (PDF:69 KB)
-
130209_DLd(1cycle) (PDF:146 KB)
-
130210_DLd(2cycle) (PDF:122 KB)
-
130211_DLd(3-6cycle) (PDF:122 KB)
-
130212_DLd(7cycle-) (PDF:122 KB)
-
130213_DBd(1cycle) (PDF:155 KB)
-
130214_DBd(2-3cycle) (PDF:138 KB)
-
130215_DBd(4-8cycle) (PDF:127 KB)
-
130216_DBd(9cycle-) (PDF:110 KB)
-
130217_ELd(1cycle) (PDF:143 KB)
-
130218_ELd(3cycle-) (PDF:125 KB)
-
130219_ELd(2cycle) (PDF:120 KB)
-
130220_KRd(1cycle) (PDF:123 KB)
-
130221_KRd(2-12cycle) (PDF:111 KB)
-
130222_KRd(13-18cycle) (PDF:124 KB)
-
130223_weeklyKd(1cycle) (PDF:110 KB)
-
130224_weeklyKd(2cycle-) (PDF:100 KB)
-
130225_DMPB(1cycle) (PDF:177 KB)
-
130226_DMPB(2-9cycle) (PDF:131 KB)
-
130227_DMPB(10cycle-) (PDF:103 KB)
-
130228_EPd(1cycle) (PDF:147 KB)
-
130229_EPd(2cycle) (PDF:123 KB)
-
130230_EPd(3cycle) (PDF:127 KB)
-
130231_EPd(4cycle-) (PDF:127 KB)
-
130232,130234_IsaPd(1cycle) (PDF:149 KB)
-
130233,130235_IsaPd(2cycle-) (PDF:130 KB)
-
130236_DLd(sc)(1cycle) (PDF:116 KB)
-
130237_DLd(sc)(2cycle) (PDF:112 KB)
-
130238_DLd(sc)(3-6cycle) (PDF:114 KB)
-
130239_DLd(sc)(7cycle-) (PDF:114 KB)
-
130240_DKd(sc)(1cycle) (PDF:158 KB)
-
130241_DKd(sc)(2cycle) (PDF:134 KB)
-
130242_DKd(sc)(3-6cycle) (PDF:129 KB)
-
130243_DKd(sc)(7cycle-) (PDF:130 KB)
-
130244_DMPB(sc)(1cycle) (PDF:141 KB)
-
130245_DMPB(sc)(2-9cycle) (PDF:124 KB)
-
130246_DMPB(sc)(10cycle-) (PDF:95 KB)
-
130247_DBd(sc)(1cycle) (PDF:129 KB)
-
130248_DBd(sc)(2-3cycle) (PDF:126 KB)
-
130249_DBd(sc)(4-8cycle) (PDF:117 KB)
-
130250_DBd(sc)(9cycle-) (PDF:101 KB)
-
130251_Isatuximab(1cycle) (PDF:137 KB)
-
130252_Isatuximab(2cycle-) (PDF:112 KB)
-
130253,130254_Isa+d(1cycle) (PDF:145 KB)
-
130255,130256_Isa+d(2cycle-) (PDF:121 KB)
-
130257_IsaKd(1cycle) (PDF:190 KB)
-
130258_IsaKd(2cycle-) (PDF:147 KB)
-
130259_BLd (PDF:86 KB)
-
130260_BLd(sc) (PDF:83 KB)
-
130261_DPd(sc)(1cycle) (PDF:117 KB)
-
130262_DPd(sc)(2cycle) (PDF:113 KB)
-
130263_DPd(sc)(3-6cycle) (PDF:114 KB)
-
130264_DPd(sc)(7cycle-) (PDF:115 KB)
ALアミロイドーシス
-
133001_DCyBorD(sc)(1-2cycle) (PDF:130 KB)
-
133002_DCyBorD(sc)(3-6cycle) (PDF:133 KB)
-
133003_DCyBorD(sc)(7cycle-) (PDF:93 KB)
白血病
-
140215_ATL_Mogamulizumab (PDF:109 KB)
-
140254_CLL_R-FC(F-Ara-A+CPA)(1cycle) (PDF:121 KB)
-
140255_CLL_R-FC(F-Ara-A+CPA)(2cycle-) (PDF:122 KB)
-
140273_ALL(induction)_Blinatumomab(45kg-)(1cycle)(4days-3days) (PDF:160 KB)
-
140274_ALL(induction)_Blinatumomab(45kg-)(2cycle)(4days-3days) (PDF:141 KB)
-
140275_ALL(consolidation)_Blinatumomab(45kg-)(4days-3days) (PDF:141 KB)
-
140276_ALL(maintenance)_Blinatumomab(45kg-)(4days-3days) (PDF:141 KB)
-
140277_ALL(induction)_Blinatumomab(45kg-)(1cycle)(3days-4days) (PDF:160 KB)
-
140278_ALL(induction)_Blinatumomab(45kg-)(2cycle)(3days-4days) (PDF:141 KB)
-
140279_ALL(consolidation)_Blinatumomab(45kg-)(3days-4days) (PDF:140 KB)
-
140280_ALL(maintenance)_Blinatumomab(45kg-)(3days-4days) (PDF:140 KB)
-
140281_ALL(induction)_Blinatumomab(-45kg)(1cycle)(4days-3days) (PDF:167 KB)
-
140282_ALL(induction)_Blinatumomab(-45kg)(2cycle)(4days-3days) (PDF:145 KB)
-
140283_ALL(consolidation)_Blinatumomab(-45kg)(4days-3days) (PDF:144 KB)
-
140284_ALL(maintenance)_Blinatumomab(-45kg)(4days-3days) (PDF:144 KB)
-
140285_ALL(induction)_Blinatumomab(-45kg)(1cycle)(3days-4days) (PDF:167 KB)
-
140286_ALL(induction)_Blinatumomab(-45kg)(2cycle)(3days-4days) (PDF:145 KB)
-
140287_ALL(consolidation)_Blinatumomab(-45kg)(3days-4days) (PDF:144 KB)
-
140288_ALL(maintenance)_Blinatumomab(-45kg)(3days-4days) (PDF:144 KB)
MDS
-
150202_Azacitidine (PDF:73 KB)
-
150204_Azacitidine(sc) (PDF:80 KB)
頭頸部がん
-
160101_BRT_Cetuximab(1cycle) (PDF:58 KB)
-
160102_BRT_Cetuximab(2cycle-) (PDF:57 KB)
-
160214_C-mab(maintenance) (PDF:64 KB)
-
160215_weekly PTX (PDF:86 KB)
-
160216_triweekly DTX (PDF:84 KB)
-
160217_Nivolumab (PDF:80 KB)
-
160220_weekly PTX+C-mab(1cycle) (PDF:72 KB)
-
160221_weekly PTX+C-mab(2cycle-) (PDF:70 KB)
-
160223_Pembrolizumab(maintenance) (PDF:83 KB)
-
160224_Pembrolizumab (PDF:80 KB)
-
160225_Pembrolizumab(Q6W)(maintenance) (PDF:84 KB)
-
160226_Pembrolizumab(Q6W) (PDF:82 KB)
-
160227_Nivolumab(Q4W) (PDF:82 KB)
-
160229_DTX+Trastuzumab(1cycle) (PDF:95 KB)
-
160230_DTX+Trastuzumab(2cycle-) (PDF:99 KB)
-
160231_Trastuzumab(maintenance) (PDF:89 KB)
-
160233_CDDP+DTX (PDF:122 KB)
MSI-High
-
270000_MSI-High_Pembrolizumab (PDF:90 KB)
TMB-High
-
270001_TMB-High_Pembrolizumab (PDF:91 KB)
胸腺腫瘍
-
013201_CAP(CPA+DXR+CDDP) (PDF:107 KB)
悪性軟部腫瘍
-
210203_AIM(ADM+IFM+Mesna) (PDF:132 KB)
-
210205_Eribulin (PDF:65 KB)
悪性神経膠腫
-
220101_Bevacizumab(Q3W) (PDF:78 KB)
-
220102_Bevacizumab(Q2W) (PDF:78 KB)
悪性黒色腫
-
015101_DTIC (PDF:83 KB)
-
250101_Nivolumab (PDF:76 KB)
-
250102_Nivolumab+Ipilimumab (PDF:87 KB)
-
250103_Nivolumab(Q4W) (PDF:78 KB)
原発不明がん
-
016101_Nivolumab (PDF:99 KB)
-
016102_Nivolumab(Q4W) (PDF:100 KB)
転移性骨腫瘍
-
210101_Denosumab (PDF:86 KB)
-
210102_Zoledronic Acid (PDF:88 KB)
PDF形式のファイルをご覧いただく場合には、Adobe Readerが必要です。
Adobe Readerをお持ちでない方は、バナーのリンク先から無料ダウンロードしてください。
